Monday, September 25, 2023
Disclosures
It is the policy of IMNE to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, faculty, CME/CE provider staff, and educational partner staff) are expected to disclose any relevant financial relationships with ineligible companies over the past 24 months. It is also required that faculty identify and reference off-label products or investigational uses of pharmaceutical agents and medical devices.
Mitigation of Relevant Financial Interests
IMNE utilizes a peer review process to mitigate potential and actual conflicts of interest disclosed by all persons in a position to influence the planning process or content development of this educational activity. All peer reviewers are without relevant financial relationships. A copy of the mitigation worksheet is available by request from [email protected]
Medical Director & Principal Investigator
Metabolic Institute of America
Tarzana, California
Preventive Cardiologist, Brigham and Women’s Hospital
Associate Professor, Medicine at Harvard Medical School
Boston, Massachusetts
Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™
Cardiologists who are interested in reducing cardiovascular risk, particularly risk of atherosclerotic cardiovascular disease, in individuals with type 2 diabetes.
The cardiovascular (CV) benefits identified in CV outcomes trials (CVOTs) for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have resulted in updated guidance from the American Diabetes Association and American Association of Clinical Endocrinology that advises use of GLP-1 RAs (or sodium glucose cotransporter 2 [SGLT2] inhibitors) in all people with or at high risk for atherosclerotic CV disease (ASCVD), regardless of glycated hemoglobin (A1C) or metformin use. The American College of Cardiology has recently released a similar recommendation in their 2020 Clinical Decision Pathway, while also calling on cardiologists to increase their involvement in screening for and treating type 2 diabetes (T2D). The cardioprotective effects of GLP-1 RAs have significantly altered the treatment landscape for people with T2D who have, or are high risk for, ASCVD, and it is critical that cardiologists are familiar with the CVOT data and prescribing recommendations for GLP-1 RAs, as well as factors that differentiate them from other glucose-lowering agents. The goal of this activity is to provide a comprehensive review of these agents and their clinical effects in order to help to increase confidence among cardiologists in integrating these therapies into practice and working with other clinicians and patients to develop treatment plans that offer the greatest chance of success.
Upon completion of this activity, participants will:
Disclosures
It is the policy of IMNE to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, faculty, CME/CE provider staff, and educational partner staff) are expected to disclose any relevant financial relationships with ineligible companies over the past 24 months. It is also required that faculty identify and reference off-label products or investigational uses of pharmaceutical agents and medical devices.
Mitigation of Relevant Financial Interests
IMNE utilizes a peer review process to mitigate potential and actual conflicts of interest disclosed by all persons in a position to influence the planning process or content development of this educational activity. All peer reviewers are without relevant financial relationships. A copy of the mitigation worksheet is available by request from [email protected]
Medical Director & Principal Investigator
Metabolic Institute of America
Tarzana, California
Preventive Cardiologist, Brigham and Women’s Hospital
Associate Professor, Medicine at Harvard Medical School
Boston, Massachusetts
IMNE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME Released: 6/1/2023
Valid for credit through: 6/1/2024, 11:59 PM EST
processing....
This CME activity was developed to be distributed on Medscape.org. The program is an online, enduring activity with videos led by expert faculty (1 endocrinologist and 1 cardiologist) considered to be key opinion leaders in type 2 diabetes and cardiology.
